journal article·2026-05-12Open access

Engineered Carbon Dots from a Traditional Herb Pair Orchestrate Concurrent Antioxidant and AP‐1‐Mediated Inflammation to Attenuate Renal Ischemia‐Reperfusion Injury

Bixiao Liu, Fuying Zhu, Zhuqing Wang, Jiawen Chen, Xiaomiao Cui, Congzhong Yang, Yao Peng, Dengyuan Feng, Li Lu, Hui Wei, Xiaozhi Zhao

Abstract

ABSTRACT Renal ischemia‐reperfusion (I/R) injury, a primary cause of acute kidney injury (AKI), is driven by a self‐amplifying loop of oxidative burst and immune cell infiltration. In this work, the classical herb pair Astragalus membranaceus (AM) and Angelica sinensis (AS) is employed as a composite precursor to synthesize nitrogen‐rich carbon‐dot nanozymes (AM‐AS@CDs) via a one‐step hydrothermal method. AM‑AS@CDs exhibit superoxide dismutase (SOD)‐mimetic activity superior to that of CDs derived from single herbs. In vitro, AM‐AS@CDs effectively alleviate oxidative stress‐induced cellular damage and significantly inhibit apoptosis. In vivo, AM‐AS@CDs markedly attenuate I/R‐induced AKI and reduce immune cell infiltration in renal tissues. Transcriptomic analyses reveal that AM‐AS@CDs downregulate the expression and phosphorylation of Fosl1 and c‐Jun. Consequently, the AP‐1‐chemokine signaling axis is disrupted, which reduces immune cell recruitment. Furthermore, AM‐AS@CDs restore redox homeostasis by upregulating antioxidant enzymes such as SOD, glutathione peroxidase 4 (GPX4), and catalase (CAT). They also attenuate the excessive activation of the Nrf2/HO‐1 pathway. Overall, this precursor‐formulation strategy enables precise modulation of heteroatom doping and surface chemistry in CDs. AM‐AS@CDs effectively interrupt the oxidative‐inflammatory positive feedback loop through dual mechanisms. These findings provide both theoretical and material foundations for the development of natural product‐based nanozymes for I/R‐related diseases.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Advanced Nanomaterials in Catalysis · Carbon and Quantum Dots Applications · Nanoplatforms for cancer theranostics

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Andrology Nanjing Drum Tower Hospital the Affiliated Hospital of Nanjing University Medical School Nanjing Jiangsu China

Department of Biomedical Engineering College of Engineering and Applied Sciences Nanjing National Laboratory of Microstructures Jiangsu Key Laboratory of Artificial Functional Materials Nanjing University Nanjing Jiangsu China

Funding

National Natural Science Foundation of China · Natural Science Foundation of Jiangsu Province

References (56)

Show source-provided references
1. 10.1038/s41581‐023‐00784‐z10.1038/s41581‐023‐00784‐z ↗
2. 10.1016/S0140‐6736(24)02385‐710.1016/S0140‐6736(24)02385‐7 ↗
3. 10.1016/j.intimp.2025.11520710.1016/j.intimp.2025.115207 ↗
4. 10.1038/s41581‐022‐00658‐w10.1038/s41581‐022‐00658‐w ↗
5. 10.1053/j.ajkd.2022.12.00810.1053/j.ajkd.2022.12.008 ↗
6. 10.1016/j.kint.2017.06.03010.1016/j.kint.2017.06.030 ↗
7. 10.1097/01.Asn.0000138232.68452.3b10.1097/01.Asn.0000138232.68452.3b ↗
8. 10.1038/nm.250710.1038/nm.2507 ↗
9. 10.1038/nri287310.1038/nri2873 ↗
10. 10.1016/j.clinsp.2025.10062710.1016/j.clinsp.2025.100627 ↗
11. 10.1016/j.tice.2025.10277510.1016/j.tice.2025.102775 ↗
12. 10.1038/nrneph.2017.10710.1038/nrneph.2017.107 ↗
13. 10.1080/0886022x.2020.176965610.1080/0886022x.2020.1769656 ↗
14. 10.1681/asn.201206063310.1681/asn.2012060633 ↗
15. 10.1038/nri352310.1038/nri3523 ↗
16. 10.3389/fimmu.2025.168820710.3389/fimmu.2025.1688207 ↗
17. 10.1016/j.semnephrol.2025.15167210.1016/j.semnephrol.2025.151672 ↗
18. 10.1038/s41581‐024‐00875‐510.1038/s41581‐024‐00875‐5 ↗
19. 10.1002/advs.20240919010.1002/advs.202409190 ↗
20. 10.1016/j.biopha.2019.10969310.1016/j.biopha.2019.109693 ↗
21. 10.1039/c8cs00457a10.1039/c8cs00457a ↗
22. 10.1021/jacs.2c0966310.1021/jacs.2c09663 ↗
23. 10.1007/s40820‐022‐00828‐210.1007/s40820‐022‐00828‐2 ↗
24. 10.1002/anie.20200410910.1002/anie.202004109 ↗
25. 10.1021/acsnano.2c0161910.1021/acsnano.2c01619 ↗
26. 10.1002/smll.20200462110.1002/smll.202004621 ↗
27. 10.1002/anie.20221404210.1002/anie.202214042 ↗
28. 10.1002/anie.20171246910.1002/anie.201712469 ↗
29. 10.1016/j.jcis.2021.12.10710.1016/j.jcis.2021.12.107 ↗
30. 10.1016/j.nantod.2023.10176810.1016/j.nantod.2023.101768 ↗
31. 10.1021/acsanm.0c0241910.1021/acsanm.0c02419 ↗
32. 10.3390/molecules3019401510.3390/molecules30194015 ↗
33. 10.3389/fphar.2025.155715110.3389/fphar.2025.1557151 ↗
34. 10.1177/1534735424131191710.1177/15347354241311917 ↗
35. 10.1016/j.jep.2024.11898210.1016/j.jep.2024.118982 ↗
36. 10.3390/molecules2813501810.3390/molecules28135018 ↗
37. 10.1016/j.biopha.2024.11642910.1016/j.biopha.2024.116429 ↗
38. 10.1021/acsabm.3c0046210.1021/acsabm.3c00462 ↗
39. 10.1186/s12951‐021‐01072‐310.1186/s12951‐021‐01072‐3 ↗
40. 10.1016/j.jcis.2020.02.01110.1016/j.jcis.2020.02.011 ↗
41. 10.1016/j.colsurfb.2019.03.01210.1016/j.colsurfb.2019.03.012 ↗
42. 10.1038/s41467‐023‐35828‐210.1038/s41467‐023‐35828‐2 ↗
43. 10.1002/agt2.16910.1002/agt2.169 ↗
44. 10.7150/thno.12621710.7150/thno.126217 ↗
45. 10.1002/smll.20210634210.1002/smll.202106342 ↗
46. 10.1038/ncomms635710.1038/ncomms6357 ↗
47. 10.1007/s40820‐020‐00539‐610.1007/s40820‐020‐00539‐6 ↗
48. 10.1016/j.apsb.2025.05.02410.1016/j.apsb.2025.05.024 ↗
49. 10.1016/j.actbio.2020.07.02210.1016/j.actbio.2020.07.022 ↗
50. 10.1016/j.bja.2025.02.00610.1016/j.bja.2025.02.006 ↗
51. 10.3390/ijms2215801010.3390/ijms22158010 ↗
52. 10.1016/j.nano.2011.03.00510.1016/j.nano.2011.03.005 ↗
53. 10.1021/acs.biomac.0c0096910.1021/acs.biomac.0c00969 ↗
54. 10.3390/cells1418144310.3390/cells14181443 ↗
55. 10.1016/j.immuni.2025.02.02310.1016/j.immuni.2025.02.023 ↗
56. 10.3349/ymj.2015.56.4.113410.3349/ymj.2015.56.4.1134 ↗